Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $638.38M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 34.97M
Average 16.28M
GERN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Geron CorporationNASDAQ: GERN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $326K rose 5.8% year over year, ahead of the -2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 18.5% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Depreciation & amortization amounted to 0.7% of revenue in FY2025, down 0.9 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5.8% holds above the trailing-twelve-month pace of -2.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.2M USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- +11.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.2M | -1.4% |
| FY2024 | 2024-12-31 | 1.22M | +18.2% |
| FY2023 | 2023-12-31 | 1.03M | +19.0% |
| FY2022 | 2022-12-31 | 868K | +10.9% |
| FY2021 | 2021-12-31 | 783K | — |
Depreciation & Amortization vs competitors
How GERN compares with its peers on the latest reported figures
- GERN's LTM Mar 2026 depreciation & amortization of $1.22M is the 4th largest of the 8 companies compared; the peer median is $873K.
- Its year-over-year change of -2.6% is the 4th highest of 6, against a peer median of -1.0%.
- Depreciation & amortization amounts to 0.6% of revenue for GERN, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $98.28M | +8.6% | +11.2% | 1.7% | |
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $1.22M | -2.6% | +11.5% | 0.6% | |
| LTM Jun 2026 | $873K | +7.1% | +5.5% | 2.5% | |
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $771K | — | -58.9% | — |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $304K | — | — | — |
| LTM Sep 2026 | $152K | -97.9% | — | — | |
| Peer median (excluding GERN) | $873K | -1.0% | +11.2% | 1.7% | |
Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| Deferred Income Tax | 191K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.08M | 8M | 19.35M | 31.32M | 88K |
| Change in Working Capital | 10.52M | 5.03M | 6.06M | (68.41M) | (68.54M) |
| Accounts Receivables | (1.04M) | (1.38M) | 1.49M | (36.89M) | (377K) |
| Inventory | 1.04M | 1.38M | 0 | (37.97M) | (77.92M) |
| Accounts Payables | (232K) | 3.5M | (4.03M) | 2.44M | 2.66M |
| Other Working Capital | 10.75M | 1.52M | 8.6M | 4.02M | 7.1M |
| Other Non-Cash Items | 984K | 626K | (10.06M) | (8.18M) | 41.99M |
| Operating Cash Flow | (95.56M) | (127.38M) | (167.74M) | (218.62M) | (111.04M) |
| Capital Expenditures | (207K) | (431K) | (830K) | (680K) | (49K) |
| Acquisitions (Net) | 1.59M | (1.23M) | 179.49M | 0 | 0 |
| Purchases of Investments | (177.43M) | (258.01M) | (475.59M) | (476.93M) | (304.42M) |
| Sales of Investments | 249.59M | 320.51M | 296.1M | 371.61M | 411.72M |
| Other Investing Activities | (1.59M) | 1.23M | (179.49M) | 0 | 0 |
| Investing Cash Flow | 71.95M | 62.07M | (180.32M) | (106M) | 107.25M |
| Debt Repayment | 24.9M | 0 | 29.7M | 34.57M | 0 |
| Common Stock Issued | 20.39M | 69.92M | 213.34M | 140.73M | 2.27M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.28M | 17.35M | 118.98M | 159.08M | 0 |
| Financing Cash Flow | 48.56M | 87.26M | 362.02M | 334.37M | 2.27M |
| Effect of Forex Changes | 0 | 22K | (27K) | (12K) | 87K |
| Net Change in Cash | 24.95M | 21.97M | 13.93M | 9.74M | (1.44M) |
| Free Cash Flow | (95.76M) | (127.81M) | (168.57M) | (219.3M) | (111.09M) |
Geron Corporation
NASDAQ:GERN
Intrinsic Alpha fair value
Locked
Current Price
$0.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.